Reuters logo
BRIEF-Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH
January 9, 2017 / 2:44 PM / 10 months ago

BRIEF-Vivus and Selten Pharma announce agreement for development and commercialization rights to treatments for PAH

Jan 9 (Reuters) - Vivus Inc

* Vivus and Selten Pharma announce agreement for the development and commercialization rights to treatments for Pulmonary Arterial Hypertension (PAH)

* Vivus assumes all development and commercialization responsibilities

* Vivus is responsible for all future financial obligations to Stanford under Stanford license

* Selten will receive an upfront payment, development and sales milestone payments, tiered royalties on future sales of compounds Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below